fecal microbiota transplant

fecal microbiota transplant. Fecal microbiota transplant is a therapeutic procedure involving the transfer of processed stool from a healthy donor into the gastrointestinal tract of a recipient. It is primarily used to treat recurrent Clostridioides difficile infection, a debilitating condition often resistant to conventional antibiotic therapy. The goal is to restore a healthy balance of gut microbiota, thereby resolving infection and associated symptoms like severe diarrhea and colitis.

Medical uses

The primary and most well-established application is for recurrent or refractory Clostridioides difficile infection, with cure rates often exceeding 90% in clinical practice. It is considered in guidelines from organizations like the American Gastroenterological Association and the European Society of Clinical Microbiology and Infectious Diseases after multiple antibiotic failures. Emerging research is investigating its potential role in other conditions linked to dysbiosis, such as ulcerative colitis, irritable bowel syndrome, and certain neurological conditions, though these remain experimental. Its use is also being explored in conjunction with immunotherapy for cancers like melanoma to modulate treatment response.

Procedure

The process begins with rigorous screening of donors, often following protocols from institutions like the OpenBiome stool bank, to exclude pathogens and ensure general health. The donor stool is processed in a laboratory, typically mixed with a saline or other solution, and filtered to remove particulate matter. Administration to the recipient is performed via several routes: colonoscopy is the most common, allowing direct delivery to the colon; other methods include nasoduodenal tube, enema, or orally administered capsules containing freeze-dried material. The choice of method is influenced by clinician preference, patient factors, and protocols from leading centers such as the Mayo Clinic.

Mechanism of action

The therapeutic effect is believed to stem from the restoration of a diverse and functional microbial community, which outcompetes pathogenic organisms like Clostridioides difficile. This is often described as "bacterial interference" or ecological restoration. The transplanted microbiota may produce metabolites like secondary bile acids that inhibit C. difficile germination and growth. Furthermore, it can modulate the host immune system, potentially reducing inflammatory responses and promoting mucosal healing in the gastrointestinal tract. The exact mechanisms are an active area of research within fields like microbiome science and immunology.

Risks and complications

While generally safe for C. difficile infection, the procedure carries risks including transmission of infectious agents from donor to recipient, despite stringent screening. Procedural risks mirror those of the delivery method, such as perforation from colonoscopy or aspiration during nasoduodenal infusion. There is a theoretical risk of transferring susceptibility to other conditions, such as obesity, asthma, or autoimmune disease, if the donor microbiota carries such predispositions. Long-term safety data is still being collected, and regulatory bodies like the U.S. Food and Drug Administration consider it an investigational drug for most uses outside of recurrent C. difficile.

History and society

The concept has historical roots, with descriptions of using human stool to treat severe diarrhea found in 4th century Chinese texts by Ge Hong. Modern medical interest was revitalized in 1958 with a report by Ben Eiseman and colleagues. The field expanded rapidly following high-profile studies published in journals like the New England Journal of Medicine and the establishment of nonprofit stool banks like OpenBiome. Its regulation varies globally; the FDA enforces an enforcement discretion policy for C. difficile, while countries like Australia and the United Kingdom have developed their own clinical guidelines. Public and media perception has evolved, with coverage in outlets like The New York Times bringing it to wider attention.

Research directions

Current investigations focus on moving from whole stool to defined microbial consortia, or "bugs as drugs," to improve consistency and safety, a direction pursued by companies like Seres Therapeutics. Research is exploring efficacy in diseases like Parkinson's disease, autism spectrum disorder, and hepatic encephalopathy. Large-scale studies are underway to better understand the long-term ecological impact on the recipient's microbiome. There is also significant interest in standardizing protocols, identifying optimal donor characteristics, and understanding the role of other stool components like bacteriophages and fungi in therapeutic outcomes. Category:Gastroenterology Category:Microbiology Category:Medical treatments